Subtypes of receptors for serotonin.

Interest in the physiological functions of 5-hydroxytryptamine (5-HT; seroto­ nin) has increased steadily since its discovery in the intestine (1) and in serum (2). Its identification in brain in the early 1950s (3), followed a decade later by the initial studies of its distribution in brain by histofluorescence (4), stimulated investigations of the possible behavioral functions of this in­ dolealkylamine. In addition to studies of its function in brain, a steady stream of investigations have described its possible functions in the periphery, particularly in the gastrointestinal tract (see 5) and, more recently, in the cardiovascular system (see 6). Indeed, the initial suggestion that there might be more than one type of receptor for 5-HT came from experiments on the isolated guinea pig ileum. Gaddum & Picarelli (7) demonstrated that only a portion of its contractile response to 5-HT could be blocked by high con­ centrations of morphine but that the remainder of the response could be

[1]  J. Gaddum,et al.  TWO KINDS OF TRYPTAMINE RECEPTOR , 1997, British journal of pharmacology and chemotherapy.

[2]  J. Williams,et al.  Serotonin agonists inhibit synaptic potentials in the rat locus ceruleus in vitro via 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors. , 1989, The Journal of pharmacology and experimental therapeutics.

[3]  R. North,et al.  5-HT3 receptors are membrane ion channels , 1989, Nature.

[4]  T. Jessell,et al.  Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. , 1989, Science.

[5]  G Vassart,et al.  Selective amplification and cloning of four new members of the G protein-coupled receptor family. , 1989, Science.

[6]  J. A. Peters,et al.  Electrophysiology of 5-HT3 receptors in neuronal cell lines. , 1989, Trends in pharmacological sciences.

[7]  C. Strader,et al.  Structural basis of β‐adrenergic receptor function , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  D. Middlemiss,et al.  Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. , 1989, Trends in pharmacological sciences.

[9]  J. Bockaert,et al.  BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. , 1989, European journal of pharmacology.

[10]  P. Hartig Molecular biology of 5-HT receptors. , 1989, Trends in pharmacological sciences.

[11]  M. Brann,et al.  Localization of a family of muscarinic receptor mRNAs in rat brain , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  E. sanders-Bush,et al.  Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. , 1988, The Journal of pharmacology and experimental therapeutics.

[13]  B. Costall,et al.  Identification of 5‐HT3 recognition sites in the ferret area postrema , 1988, The Journal of pharmacy and pharmacology.

[14]  T. Jessell,et al.  Molecular characterization of a functional cDNA encoding the serotonin 1c receptor. , 1988, Science.

[15]  J. Bockaert,et al.  5-HT1B receptors are negatively coupled with adenylate cyclase in rat substantia nigra. , 1988, European journal of pharmacology.

[16]  T. Bonner,et al.  Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes , 1988, Neuron.

[17]  N. Ropert Inhibitory action of serotonin in CA1 hippocampal neurons In vitro , 1988, Neuroscience.

[18]  G. Aghajanian,et al.  Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons , 1988, Neuropharmacology.

[19]  C. Swain,et al.  [3H]quaternised ICS 205-930 labels 5-HT3 receptor binding sites in rat brain. , 1988, European journal of pharmacology.

[20]  B. Costall,et al.  The potential anxiolytic activity of GR38032F, a 5‐HT3‐receptor antagonist , 1988, British journal of pharmacology.

[21]  S. Peroutka,et al.  [3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes. , 1988, European journal of pharmacology.

[22]  H. Vijverberg,et al.  Pharmacological characterization of serotonin 5-HT3 receptor-mediated electrical response in cultured mouse neuroblastoma cells , 1988, Neuropharmacology.

[23]  J. Bockaert,et al.  Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. , 1988, Molecular pharmacology.

[24]  J. Bockaert,et al.  A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930. , 1988, European journal of pharmacology.

[25]  G. Aghajanian,et al.  Pertussis toxin blocks 5-HT1A and GABAB receptor-mediated inhibition of serotonergic neurons. , 1987, European journal of pharmacology.

[26]  R. Glennon,et al.  Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand. , 1987, Biochemical pharmacology.

[27]  E. Hansson,et al.  5-Hydroxytryptamine stimulates the formation of inositol phosphate in astrocytes from different regions of the brain , 1987, Neuropharmacology.

[28]  M. Caron,et al.  An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins , 1987, Nature.

[29]  G. Martin,et al.  Differential classification of vascular smooth muscle and endothelial cell 5‐HT receptors by use of tryptamine analogues , 1987, British journal of pharmacology.

[30]  M. Vivo,et al.  Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate , 1987, Brain Research.

[31]  H. van Belle,et al.  Serotonin-induced alterations in inositol phospholipid metabolism in human platelets. , 1987, Biochimica et biophysica acta.

[32]  M. Titeler,et al.  3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors. , 1987, Molecular pharmacology.

[33]  U. Leli,et al.  Stimulation of Phosphoinositide Hydrolysis by Serotonin in C6 Glioma Cells , 1987, Journal of neurochemistry.

[34]  T. Branchek,et al.  Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Meltzer,et al.  Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat Evidence for opposing roles of 5-HT2 and 5-HT1A receptors , 1986, Neuropharmacology.

[36]  G. Aghajanian,et al.  Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonists , 1986, Brain Research.

[37]  C. de Montigny,et al.  In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  G. Allen,et al.  Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors. , 1986, The Journal of pharmacology and experimental therapeutics.

[39]  W. Feniuk,et al.  5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. , 1986, Life sciences.

[40]  M. Minchin,et al.  Serotonergic agonists stimulate inositol lipid metabolism in rabbit platelets. , 1985, Life sciences.

[41]  M. Hirata,et al.  A role for inositol 1,4,5‐trisphosphate in the initiation of agonist‐induced contractions of dog tracheal smooth muscle , 1985, British journal of pharmacology.

[42]  P. Conn,et al.  Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions. , 1985, The Journal of pharmacology and experimental therapeutics.

[43]  J. Leysen,et al.  Evidence that phospholipid turnover is the signal transducing system coupled to serotonin-S2 receptor sites. , 1985, Journal of Biological Chemistry.

[44]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[45]  M. Titeler,et al.  Guanyl Nucleotide and Divalent Cation Regulation of Cortical S2 Serotonin Receptors , 1984, Journal of neurochemistry.

[46]  G. Aghajanian,et al.  Hyperpolarization of serotonergic neurons by serotonin and LSD: Studies in brain slices showing increased K+ conductance , 1984, Brain Research.

[47]  C. Wilkinson,et al.  5-Hydroxytryptamine receptor in rabbit aorta: characterization by butyrophenone analogs. , 1984, The Journal of pharmacology and experimental therapeutics.

[48]  J. Glowinski,et al.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT , 1983, Nature.

[49]  J. Leysen Serotonin receptor binding sites: is there pharmacological and clinical significance? , 1983, Medical biology.

[50]  A. Closse [3H]Mesulergine, a selective ligand for serotonin-2 receptors. , 1983, Life sciences.

[51]  Herman Ag,et al.  5-hydroxytryptamine and platelet aggregation. , 1983 .

[52]  Van Nueten Jm 5-hydroxytryptamine and precapillary vessels. , 1983, Federation proceedings.

[53]  Y. Saito,et al.  5-HT-stimulated arachidonic acid release from labeled phosphatidylinositol in blowfly salivary glands. , 1982, The American journal of physiology.

[54]  P. Molinoff,et al.  Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes. , 1981, Life sciences.

[55]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[56]  R. Mccall,et al.  Serotonergic facilitation of facial motoneuron excitation , 1979, Brain Research.

[57]  J. Leysen,et al.  A serotonergic component of neuroleptic receptors. , 1977, Archives internationales de pharmacodynamie et de therapie.

[58]  S. O'Donnell,et al.  THE CONTRIBUTION OF EXTRANEURONAL UPTAKE TO THE TRACHEA‐BLOOD VESSEL SELECTIVITY OF β‐ADRENOCEPTOR STIMULANTS in vitro IN GUINEA‐PIGS , 1976, British journal of pharmacology.

[59]  H. van Vunakis,et al.  Characteristics of D-lysergic acid diethylamide binding to subcellular fractions derived from rat brain. , 1973, Biochemical pharmacology.

[60]  D. Grahame-Smith STUDIES IN VIVO ON THE RELATIONSHIP BETWEEN BRAIN TRYPTOPHAN, BRAIN 5‐HT SYNTHESIS AND HYPERACTIVITY IN RATS TREATED WITH A MONOAMINE OXIDASE INHIBITOR AND L‐TRYPTOPHAN , 1971, Journal of neurochemistry.

[61]  T. Rall,et al.  The influence of chemical agents on the accumulation of adenosine 3',5'-Phosphate in slices of rabbit cerebellum. , 1968, Molecular pharmacology.

[62]  T. Rall,et al.  Studies on adenosine 3',5'-phosphate in rabbit cerebral cortex. , 1968, Molecular pharmacology.

[63]  G. Aston-Jones,et al.  [Selective reduction by serotonin, of neuronal excitation in the locus coeruleus evoked by glutamate]. , 1988, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[64]  M. Vivo,et al.  5-HT Receptors Coupled to Adenylate Cyclase , 1988 .

[65]  G. Aghajanian,et al.  Electrophysiology of Central Serotonin Receptor Subtypes , 1988 .

[66]  M. Titeler,et al.  Pharmacology and Biochemistry of the 5-HT2 Receptor , 1988 .

[67]  E. Frohlich The Role of Serotonin in Cardiovascular Disease , 1987, Journal of cardiovascular pharmacology.

[68]  R. Iyengar,et al.  Regulation of hormone receptors and adenylyl cyclases by guanine nucleotide binding N proteins. , 1985, Recent progress in hormone research.

[69]  I. Lucki,et al.  Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. , 1984, The Journal of pharmacology and experimental therapeutics.

[70]  P. Greengard,et al.  Serotonin stimulates phosphorylation of Protein I in the facial motor nucleus of rat brain , 1981, Nature.

[71]  K. Fuxe,et al.  EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.

[72]  M. Rapport,et al.  Purification of the substance which is responsible for the vasoconstrictor activity of serum. , 1947, Federation proceedings.